Presented at the 26th North American ISSX and JSSX Meeting, September 2024
Jingjing Yu, Yan Wang, and Isabelle Ragueneau-Majlessi
Abstract
The mechanistic evaluation of enzyme- and transporter-based drug-drug interactions (DDIs) is an integral part of the drug development process and supports the safe and effective clinical use of new therapies. In the present work, DDI data for small molecular drugs approved by the U.S. Food and Drug Administration in 2023 (N = 38) were analyzed using the Certara Drug Interaction Database. The mechanism(s) and clinical magnitude of the observed interactions were characterized based on information available in the new drug application reviews.